Breast Cancer Facts & Figures 2024-2025

About 80% of breast cancers are hormone receptor positive (HR+), influencing subtype classification, prognosis, and treatment response; for example, Luminal A (HR+/HER2-) cancers have the best prognosis and respond well to hormone therapy.

Approximately 1 in 8 women (13.1%) will be diagnosed with invasive breast cancer in her lifetime, and 1 in 43 (2.3%) will die from the disease.

In 2024, an estimated 310,720 new invasive breast cancers and 56,500 cases of ductal carcinoma in situ will be diagnosed among women, with about 42,250 women and 530 men expected to die from the disease.

White women have the highest incidence rates (138 per 100,000), while Black women have the highest mortality rates (27 per 100,000).

The breast cancer death rate has dropped by 44% since 1989 due to advances in treatment and earlier detection, resulting in approximately 517,900 averted breast cancer deaths.

The 5-year relative survival rate for breast cancer is 91%, dropping to 86% at 10 years and 81% at 15 years after diagnosis.

The 5-year relative survival rate is over 99% for localized stage, 87% for regional stage, and 32% for distant stage breast cancer.

HR+/HER2- (hormone receptor-positive, HER2-negative) breast cancer is the most common subtype, with the highest prevalence (73%) among White women.

Black women are most likely, with 1 in 5 cases being triple-negative breast cancer, which is more aggressive and harder to treat.

The strongest risk factors are a personal or family history of breast cancer, certain genetic mutations (such as BRCA1 and BRCA2), and high-dose radiation to the chest.

About 30% of breast cancer cases can be attributed to modifiable risk factors, notably excess body weight (postmenopausal), physical inactivity, and alcohol consumption.

Black and American Indian/Alaska Native women are least likely to be diagnosed with localized-stage breast cancer and most likely to be diagnosed at a late or unstaged stage, contributing to higher mortality.

An estimated 67% of women ages 40 and older had a screening in the past two years, ranging from 51% of American Indian/Alaska Native women to 73% of Black women. Screening prevalence by state ranges from 58% in Wyoming to 77% in Rhode Island.

Women aged 40-44 have the option to start annual screening, ages 45-54 should get annual screening, and 55+ can switch to biennial screening or continue yearly, as long as life expectancy is at least 10 years.

Male breast cancer is rare (<1% of cases), but men are more likely to be diagnosed at advanced stage due to absence of screening. Black men have the highest incidence and mortality among men.

From 2012 to 2021, breast cancer incidence increased annually by about 1% overall, with steeper increases observed among younger women (<50 years) and Asian American/Pacific Islander women (2.6% per year).

Abortion, wearing a bra, and breast implants are not associated with increased breast cancer risk.

Black women have 5% lower incidence but 38% higher mortality than White women, largely due to later diagnosis and less access to high-quality treatment.

Services include a 24/7 helpline, patient education, survivor network, temporary lodging (Hope Lodge), peer support (Reach To Recovery), transportation assistance (Road To Recovery), and more.

Inherited BRCA1 and BRCA2 mutations account for 5–10% of all breast cancers and 15–20% of familial breast cancers.

About 80% of breast cancers are hormone receptor positive (HR+), influencing subtype classification, prognosis, and treatment response; for example, Luminal A (HR+/HER2-) cancers have the best prognosis and respond well to hormone therapy.

Approximately 1 in 8 women (13.1%) will be diagnosed with invasive breast cancer in her lifetime, and 1 in 43 (2.3%) will die from the disease.